Study summary · research use only
Oxytocin in cesarean-sections. What's new?
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses oxytocin as the uterotonic agent of choice for prevention and treatment of postpartum uterine atony in cesarean sections in human patients, noting there is no consensus on the optimal dose and rate for this use. The review states high bolus doses (e.g., 10 IU of oxytocin) can cause deleterious cardiovascular changes, particularly in situations of hypovolemia or low cardiac reserve, and that high doses of oxytocin given for prolonged periods may lead to desensitization of oxytocin receptors in the myometrium, resulting in reduced clinical effect.
Abstract
Oxytocin is the uterotonic agent of choice in the prevention and treatment of postpartum uterine atony. Nevertheless, there is no consensus on the optimal dose and rate for use in cesarean sections. The use of high bolus doses (e.g., 10IU of oxytocin) can determine deleterious cardiovascular changes for the patient, especially in situations of hypovolemia or low cardiac reserve. Furthermore, high doses of oxytocin for prolonged periods may lead to desensitization of oxytocin receptors in myometrium, resulting in clinical inefficiency.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.